In EGFR-mutated non-small cell lung cancer, Qianet al. [36] identified a novel E3 ubiquitin ligase, MARCH8, which can mediate the degradation of PD-L1 induced by EGFR inhibition. Here, MARCHF8 is linked to non-small cell lung carcinoma.